A human trial of Gastrodia elata Blume and Glycyrrhiza uralensis Fischer extracts mixture on improvement of Cognitive(memory) Function

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Gastrodia elata Blume and Glycyrrhiza uralensis Fischer extracts mixture on improvement of Cognitive(memory) Function

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007338

Enrollment

100

Registered

2022-05-27

Start date

2022-04-07

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : - Gastrodia elata Blume and Glycyrrhiza uralensis Fischer extracts mixture group: twice a day, 2 capsules once, after breakfast/dinner, for 12 weeks(1.4 g/day, 1g/day for Gastrodi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Those who complain of subjective memory loss {one or more points in the subjective memory loss questionnaire (SMCQ)} 2) Those who Korean-Mini Mental State Examination(K-MMSE) results in 18~28 scores 3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions.

Exclusion criteria

Exclusion criteria: 1)Patients with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 2)Patients with a history of antipsychotic medication use within 3 months prior to the screening examination 3)Patients with a history of clinically significant hypersensitivity reactions to drugs and test products 4)Patients who have participated in other clinical trials within 3 months prior to the screening examination 5)Patients with a Severe score of 29-63 points as a result of the Depression Scale (BDI) test 6)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Design outcomes

Primary

Measure	Time frame
Alzheimer's Disease Assessment Scale-cognitive subscale	—

Secondary

Measure	Time frame
Korean Mini-Mental Status Examination;Subject Memory Complain Questionnaire;Perceived stress scale);Beck Depression Inventory;Brain-derived neurotrophic factor;amyloid ß	—

Countries

Korea, Republic of

Contacts

Public ContactSangkwan Lee

Wonkwang University

forher3@gmail.com+82-62-670-6407

Outcome results